Across TCGA pan-cancer cohorts, OAZ1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated OAZ1 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher OAZ1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OAZ1 expression acts as an unfavorable survival marker.
LUSC and BLCA are the cancer types where OAZ1 Mutation most reproducibly stratifies survival.